PHARMACOLOGY UPDATE | ANTIMICROBIAL THERAPY

June 2026 | NP Chronicles Clinical Education

Zaynich Is Here: What NPs Need to Know About the FDA's Newest Antibiotic for Complicated UTI

By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC

CLINICAL BOTTOM LINE

Cefepime-zidebactam (Zaynich) received FDA approval in June 2026 for complicated UTI (cUTI) and acute pyelonephritis (AP) caused by susceptible gram-negative pathogens, including drug-resistant strains. In the pivotal Phase 3 trial, it outperformed meropenem at the primary endpoint (89% vs. 68.4%) — a clinically meaningful difference that NPs treating hospitalized patients with resistant infections need to know.

Why This Approval Matters

Antimicrobial resistance is one of the defining clinical challenges of our era. For NPs working in hospital-based, telehealth urgent care, or primary care settings, complicated urinary tract infections — especially those caused by multidrug-resistant (MDR) organisms — represent a growing clinical headache. Patients with MDR infections face longer hospitalizations, higher acuity care, and significantly increased risk of life-threatening complications.

On June 1, 2026, the FDA approved cefepime-zidebactam (brand name Zaynich, manufactured by Wockhardt) for the treatment of complicated urinary tract infections, including acute pyelonephritis, in adults. This is not just another me-too antibiotic. Its mechanism, spectrum of activity, and Phase 3 performance data make it a genuinely exciting addition to the antimicrobial toolkit — and NPs need to be able to speak to it confidently.

Mechanism of Action: What Makes Zaynich Different

Zaynich is a combination antibiotic — a fixed-dose pairing of two distinct agents:

• Cefepime — a fourth-generation cephalosporin with broad gram-negative activity that most NPs are already familiar with. It works by binding penicillin-binding proteins (PBPs), disrupting bacterial cell wall synthesis.

• Zidebactam — the novel component. Zidebactam is a bicyclo-acyl hydrazide compound that serves a dual role: it functions as a beta-lactamase inhibitor AND as a non-beta-lactam antibacterial in its own right. Unlike traditional beta-lactamase inhibitors (think clavulanate or tazobactam), zidebactam enhances the activity of cefepime against resistant organisms through an independent binding mechanism.

This dual mechanism matters clinically. Many MDR gram-negative organisms resist standard beta-lactams through extended-spectrum beta-lactamase (ESBL) production, carbapenemase expression, or porin channel modifications. Zidebactam helps overcome several of these resistance mechanisms, extending the reach of cefepime into territory where it would otherwise fail.

Spectrum of Activity: Know Your Organisms

Zaynich is FDA-indicated for cUTI and AP caused by the following susceptible gram-negative organisms:

• Enterobacter cloacae complex

• Escherichia coli

• Klebsiella pneumoniae

• Proteus mirabilis

• Pseudomonas aeruginosa

That last organism is particularly noteworthy. Pseudomonas aeruginosa is intrinsically resistant to many antibiotics and is a frequent culprit in healthcare-associated infections. Its inclusion in the Zaynich coverage profile — along with Klebsiella pneumoniae (a common ESBL and carbapenemase producer) — is a major part of this drug's clinical value proposition.

Clinical pearl: Susceptibility testing is still essential. Zaynich is indicated for susceptible organisms — it is not a blanket MDR coverage drug. Culture and sensitivity results should always guide therapy. The indication language specifies 'susceptible' strains.

Phase 3 Trial Data: ENCHANCE-1

Trial Design

The FDA approval was supported by data from the Phase 3 ENCHANCE-1 trial (ClinicalTrials.gov: NCT04979806). Key design parameters:

• Randomized, double-blind, multicenter trial

• 530 adult patients enrolled

• 64 sites across the United States, Europe, Latin America, China, and India

• Hospitalized adults with cUTI or acute pyelonephritis

• Comparator arm: meropenem — the current gold-standard carbapenem

Primary Endpoint Results

The primary endpoint was a composite of:

• Complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid baseline), AND

• No new cUTI or AP symptoms, AND

• Microbiologic eradication of the baseline pathogen (defined as reduction to <1,000 CFU/mL)

Primary endpoint result: Cefepime-zidebactam 89.0% vs. Meropenem 68.4%

Treatment difference: +20.6% (95% CI: 12.3–29.5) — statistically and clinically significant

This is a substantial margin of superiority over meropenem, a drug that is considered highly effective for serious gram-negative infections. A 20-percentage-point difference in clinical and microbiologic response is a meaningful outcome, not merely a statistical artifact.

Secondary Endpoints

The picture becomes more nuanced when examining secondary endpoints:

• Clinical cure rate: cefepime-zidebactam 97.5% vs. meropenem 97.8% — essentially equivalent, with clinical non-response at 2.5% vs. 2.2% respectively.

• Microbiologic eradication (<1,000 CFU/mL) at end of treatment: 98.2% (study drug) vs. 98.5% (meropenem) — again, virtually identical.

At first glance, these secondary results may seem to undercut the impressive primary endpoint finding. But the divergence makes sense: the primary endpoint was a composite assessed at test-of-cure, while the secondary microbiologic and clinical endpoints were assessed at end of treatment — a different timepoint. The higher primary endpoint success with cefepime-zidebactam likely reflects a faster and more complete early response, rather than a difference in ultimate cure rates.

Safety and Tolerability

Cefepime-zidebactam was generally well tolerated in the trial, though there was a numerically higher rate of treatment-emergent adverse events (TEAEs) compared to meropenem:

• Cefepime-zidebactam: 31.8% TEAE rate

• Meropenem: 28.2% TEAE rate

This approximately 3.6 percentage-point difference was not described as statistically significant or clinically alarming in the trial data. NPs should counsel patients about the possibility of adverse effects (which are consistent with the cephalosporin class — GI disturbance, hypersensitivity reactions, and the rarely-reported cefepime-associated neurotoxicity). Prescribers should review the full prescribing information (PI) for the complete safety profile before use.

Important: Cefepime is known to carry a risk of neurotoxicity (encephalopathy, myoclonus, seizures) in patients with renal impairment who are not dose-adjusted. This risk applies to the cefepime component of Zaynich. Renal dosing adjustments will be critical for your hospitalized cUTI patients.

How NPs Should Think About This Drug

Who Is This For?

Zaynich is not intended as a first-line agent for uncomplicated UTIs — those should still be managed with guideline-directed first-line therapy (nitrofurantoin, TMP-SMX, fosfomycin where appropriate). Zaynich is positioned for:

• Hospitalized adults with cUTI or acute pyelonephritis caused by MDR gram-negative organisms

• Patients who have failed or cannot receive standard therapy due to resistance patterns

• Infections involving Pseudomonas aeruginosa or resistant Klebsiella pneumoniae confirmed on culture and sensitivity

• Healthcare-associated UTIs where MDR pathogen prevalence is higher

Practice Setting Considerations

In your hospital or acute care practice, this drug will likely be initiated by ID (infectious disease) consult or attending physicians, with NPs involved in monitoring and management. In acute care NP roles with prescriptive authority for inpatient antimicrobials, understanding the indication, dosing rationale, and safety monitoring needs will be essential.

For outpatient or telehealth NPs: you will not be prescribing this drug in your practice. However, you will be seeing patients post-discharge on step-down therapy, managing follow-up, and interpreting culture results that may have initially driven the Zaynich selection. Understanding the rationale for its use is clinically and professionally important.

Regulatory Context

It is worth noting that cefepime-zidebactam has also been approved by the Drugs Controller General of India, and a marketing authorization application has been submitted to the European Medicines Agency (EMA). This drug is entering global markets — you may encounter it in patients who have received care internationally, or in future updated clinical guidelines.

For NP Students and Board Exam Prep

As you prepare for your board certification exams, you are not expected to know every newly approved agent in detail. However, understanding antibiotic class mechanisms and the clinical reasoning behind combination antibiotics is absolutely fair game. Here's how to frame Zaynich in your mental model:

• Cephalosporins (including cefepime, the 4th generation): Know your generation coverage. 4th gen cephalosporins cover gram-negatives including Pseudomonas. They work via PBP binding and cell wall inhibition.

• Beta-lactamase inhibitors: Understand that resistance to beta-lactams is frequently mediated by beta-lactamase enzyme production. Inhibitors like zidebactam (or the older clavulanate, sulbactam, tazobactam) help restore activity. The key board distinction: inhibitors do not have strong standalone antibacterial activity on their own — they potentiate the partner drug.

• Zidebactam is a novel exception: it has dual activity (inhibitor + direct antibacterial). This is a newer pharmacologic concept — know it for clinical practice, not necessarily for board exams at this point.

• Combination antibiotics are frequently used for resistant organisms — think piperacillin-tazobactam, amoxicillin-clavulanate. Adding Zaynich to your mental library of 'drug + beta-lactamase inhibitor' combinations is clinically sound.

Clinical Pearls: Zaynich at a Glance

• Generic name: Cefepime-zidebactam | Brand name: Zaynich | Manufacturer: Wockhardt

• FDA approval: June 2026 | Indication: cUTI and acute pyelonephritis in adults

• Route: IV (intravenous — this is a hospital-based drug, not oral therapy)

• Mechanism: Cephalosporin cell wall inhibitor + beta-lactamase inhibitor with direct antibacterial activity

• Coverage: E. coli, K. pneumoniae, P. aeruginosa, E. cloacae complex, P. mirabilis — susceptible strains only

• Phase 3 superiority over meropenem at primary endpoint: 89.0% vs. 68.4%

• Dose-adjust for renal impairment — cefepime-related neurotoxicity risk

• Culture and sensitivity results must guide use — not empiric for routine cUTI

The Bigger Picture

The FDA approval of Zaynich is a small but meaningful win in the ongoing fight against antimicrobial resistance. The development of truly novel antibiotic mechanisms has been sluggish for decades — the antibiotic pipeline is chronically underfunded and under-incentivized. Drugs like cefepime-zidebactam represent the kind of targeted innovation that the field needs more of.

For NPs, the clinical takeaway is practical: know when this drug is appropriate, understand what it covers and what it doesn't, and be equipped to discuss it with patients and colleagues. As NPs continue to take on larger roles in acute and complex care, pharmacologic fluency — including with newly approved agents — is a marker of professional excellence.

Stay current. Stay sharp. That's what NP Chronicles is here to help you do.

References & Resources

• Callaghan ML. FDA Approves Zaynich for cUTI. Infectious Disease Special Edition. June 1, 2026. idse.net

• ENCHANCE-1 Trial: ClinicalTrials.gov Identifier NCT04979806

• Wockhardt Press Release on Zaynich FDA Approval, June 2026

• Zaynich (cefepime-zidebactam) Full Prescribing Information — available via FDA.gov

• IDSA Clinical Practice Guidelines for the Diagnosis and Treatment of Complicated Urinary Tract Infections

This post is intended for educational purposes. Always consult the full prescribing information and current clinical guidelines for patient care decisions.

Nurse Practitioner Chronicles